March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.S. FDA has approved its Glatiramer Acetate Injection, a generic version of Teva's Copaxone, for the treatment of adult patients ...

In the late 1960s, three Weizmann Institute of Science researchers developed several protein-like molecules, called copolymers, that they believed would produce a disease similar to multiple sclerosis ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's (TEVA ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.